Disc Medicine, Inc.
IRON · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.01 | 0.18 | -1.17 | -0.01 |
| FCF Yield | -5.40% | -5.71% | -205.09% | -118.35% |
| EV / EBITDA | -14.66 | -12.21 | 3.64 | 1.87 |
| Quality | ||||
| ROIC | -27.39% | -26.24% | -26.68% | -36.69% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.96 | 0.90 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -28.39% | -73.46% | -53.62% | 15.67% |
| Safety | ||||
| Net Debt / EBITDA | 1.50 | 4.70 | 4.08 | 2.62 |
| Interest Coverage | -226.78 | 0.00 | 0.00 | -14.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |